Diabetes and Stroke: What Are the Connections?

"Disclosure: OM: Advisory Board: Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, and BOL Pharma; research grant support through Hadassah Medical Center: Novo Nordisk and AstraZeneca; Speakers bureau: Novo Nordisk, AstraZeneca, Eli Lilly, Sanofi, Merck Sharp & Dohme and Boehringer Ingelheim.: AYYC: Honoraria for speaking or consulting from Abbott, AstraZeneca, Bayer, Bausch, Boehringer Ingelheim, Dexcom, Eli Lilly, Janssen, Insulet, Medtronic, Merck, Novo Nordisk, Sanofi, HLS Therapeutics and Takeda; participation in clinical trials supported by Boehringer Ingelheim, Eli Lilly, Sanofi and Applied Therapeutics.: AAR: Advisory board member for AstraZeneca and Novo Nordisk; adverse event adjudication for trials funded by Boston Scientific and Boehringer Ingelheim; grant from Chiesi for an investigator-initiated project.: SS: Personal fees from Abbott, Allergan, AstraZeneca, Eli Lilly, Lundbeck, Novartis, Novo Nordisk, and Teva as speaker or advisor; fees from Medscape, Neurodiem Ology Medical Education for CME/education; research grants from Allergan, Novartis and Lusofarmaco; non-financial support from Abbott, Allergan, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Lundbeck, Medtronic, Novartis, Pfizer, Starmed and Teva; co-chair guideline board for European Stroke Organization; board member of the European Headache Federation; specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology journals; associate editor for The Journal of Headache and Pain; assistant editor for Stroke journal."

"Medical writing and editorial support, under the guidance of the authors, were provided by Beth Campbell, BSc, Alice Garrett, BSc MSc, and Izabel James, MBBS, from Ashfield MedComms, an Inizio company, funded by Novo Nordisk A/S. Novo Nordisk funded the medical writing support for this review and also had a role in the review of the manuscript for scientific accuracy."